Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Abstract Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in the Phase 3 BOSTON study, once weekly selinexor, on...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Maria V. Mateos, Maria Gavriatopoulou, Thierry Facon, Holger W. Auner, Xavier Leleu, Roman Hájek, Meletios A. Dimopoulos, Sosana Delimpasi, Maryana Simonova, Ivan Špička, Ludĕk Pour, Iryna Kriachok, Halyna Pylypenko, Vadim Doronin, Ganna Usenko, Reuben Benjamin, Tuphan K. Dolai, Dinesh K. Sinha, Christopher P. Venner, Mamta Garg, Don A. Stevens, Hang Quach, Sundar Jagannath, Philippe Moreau, Moshe Levy, Ashraf Z. Badros, Larry D. Anderson, Nizar J. Bahlis, Michele Cavo, Yi Chai, Jacqueline Jeha, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Paul G. Richardson, Sebastian Grosicki
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2021-04-01
Schriftenreihe:	Journal of Hematology & Oncology
Schlagworte:	Selinexor Exportin-1 Multiple myeloma SINE compound
Online-Zugang:	https://doi.org/10.1186/s13045-021-01071-9
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!